t(1;1)(q23;q42) IRF2BP2::NTRK1
Oncogenic mechanisms
Constitutive activation of TRK pathway
Targeted therapy
Larotrectinib
entrectinib
Tumor type
Thyroid cancer
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 33747210 | 2021 | Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma. | 79 |
| 32737449 | 2020 | Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. | 67 |
| 32860002 | 2021 | Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. | 50 |
| 33923728 | 2021 | NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis. | 32 |
| 38835742 | 2024 | Difficulties of Preoperative Diagnosis of Cribriform Morular Thyroid Carcinoma. | 22 |
| 31763365 | 2019 | Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report. | 17 |
| 33134460 | 2020 | Disseminated non-Langerhans cell histiocytosis with an IRF2BP2-NTRK1 gene fusion identified by next-generation sequencing. | 10 |
| 30691963 | 2019 | Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer. | 0 |
